� GenoMed� (OTC Pink Sheets GMED.PK), the Public Health Company�, announced that it is celebrating the sixth day of remembrance of the publication of its paper showing how to keep 90% of kidney failure.
Diabetes and high blood pressure drive 90% of kidney failure. Sixty meg Americans have high blood pressure and are at risk for kidney failure, and 20 million Americans have diabetes. Diabetes actually leads high blood insistency as the #1 cause of kidney failure.
Over 100,000 new patients go on the kidney machine (dialysis) each year. There are far too few kidney transplants for all these patients. There are currently over half a trillion patients on dialysis. Once on dialysis, life expectancy is quite limited - less than five years, on modal.
GenoMed's paper shows that kidney failure can be reversed early on in the course of the disease, ahead a common marker of kidney failure, the serum creatinine, reaches 2. GenoMed's is still the entirely paper in the medical literature display that it's possible to reverse chronic kidney disease in whites and blacks. Blacks go on dialysis 5 times more than whites. The company has a pending patent on its intervention, which uses already existing, generic drugs, but at novel doses.
Dr. David Moskowitz, GenoMed's CEO and the writer of the paper, aforementioned, "It's overly bad that our newspaper remains unknown. Perhaps we could bear gotten more publicity if the two agencies which sponsored the critical research in my laboratory 15 years ago, the American Diabetes Association and the Missouri Kidney Program, had said something about the paper when it came out in 2002, or since. Or if the National Kidney Foundation, which actively screens patients for kidney failure, had mentioned that there's now a way to prevent kidney failure."
Continued Dr. Moskowitz, "Or if Medicare, which pays $25 billion a year for dialysis and transplantation, had shown the slightest interest in cutting its budget by 90% when I briefed the Medical Director in 2004. Or if academic nephrology divisions wanted to actually eliminate disease, as academics did 50 years ago. Or if the National Institutes of Health wanted to do something for taxpayers after all these years of huge budgets. The NIH actually has a National Kidney Disease Education Program which would be perfect for getting the word out to the 80 million Americans who want to know."
Dr. Moskowitz ended by saying, "We have a healthcare organisation that says it wants to cure diseases. It extracts an enormous sum of money from taxpayers. The boilersuit healthcare budget in the US is over $2 trillion a year. Health insurance plans, by their own entrance fee, refuse to spend a dime on preventing disease. By its collective secretiveness and inactivity, the health care system has shown me these past 6 geezerhood that what it really wants to do is keep common diseases around, and persist in to make money from them. A dialysis patient brings in $100K a year. Healthcare needs to be wholly overhauled in this country if taxpayers want to get their money's worth. And anybody who contributes money to a nonprofit should think twice. Does that nonprofit organization really want to pose itself out of business in the next few years? If not, you're wasting your money, and, much more than importantly, your time and your leslie Townes Hope."
About GenoMed
In addition to reversing chronic kidney bankruptcy, GenoMed was recently awarded a patent for treating acute kidney failure without dialysis. GenoMed estimates that it can already spare 10% of healthcare costs and carry life by 5 long time. Patients with early kidney failure ar encouraged to contact Dr. Moskowitz at dwmoskowitz@genomed.com about joining GenoMed's Clinical Outcomes Improvement Program (COIP�). http://www.genomed.com
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or like expressions are intended to identify "modern statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the frontwards looking statements as a result of a number of risks and uncertainties, including only not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this compact release and should not be relied upon as of whatsoever subsequent date. Unless other than required by applicable jurisprudence, we specifically disclaim whatever obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or luck after the date of such statement.
GenoMed
More info
Monday, 8 September 2008
Subscribe to:
Comments (Atom)